Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Portobello SpA

    MCap

    EUR16m

    Last close

    EUR2.90

    ▲ 0.52 (21.85%)

    ArborGen Holdings

    MCap

    NZD77m

    Last close

    NZD0.15

    ▲ 0.01 (7.14%)

    ICL Group

    MCap

    USD5,729m

    Last close

    USD4.44

    ▲ 0.29 (6.99%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – Shield Therapeutics

Executive interview – Shield Therapeutics

Shield Therapeutics — 2 videos in collection

More on this equity

Shield Therapeutics is a commercial-stage speciality pharmaceutical company based in the United Kingdom that listed on AIM in 2016. Its primary focus is the commercialisation of Feraccru, approved by the EMA for the treatment of iron deficiency, with or without anaemia. Commercialisation of Feraccru in key markets (ex US) is in the hands of distribution partners Norgine, AOP Orphan and Ewopharma. In this video, the company’s CEO and co-founder Carl Sterritt introduces the company and Feraccru, discusses the recently announced positive top-line data from a Phase IIIb marketing study (AEGIS-H2H) and the commercialisation strategy for Feraccru in the US once a decision on regulatory approval is reached by the US FDA (PDUFA date of 27 July 2019).

< Previous
Next >

You may also be interested in these:

Healthcare

Bitesize briefing - Shield Therapeutics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free